Trulieve Cannabis (NYSE:TRLV – Get Free Report) and Journey Medical (NASDAQ:DERM – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, dividends and risk.
Valuation & Earnings
This table compares Trulieve Cannabis and Journey Medical”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Trulieve Cannabis | $1.18 billion | 1.80 | -$116.38 million | $0.11 | 100.41 |
| Journey Medical | $61.86 million | 2.02 | -$11.43 million | ($0.22) | -20.09 |
Journey Medical has lower revenue, but higher earnings than Trulieve Cannabis. Journey Medical is trading at a lower price-to-earnings ratio than Trulieve Cannabis, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings and target prices for Trulieve Cannabis and Journey Medical, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Trulieve Cannabis | 1 | 1 | 1 | 0 | 2.00 |
| Journey Medical | 1 | 0 | 2 | 0 | 2.33 |
Trulieve Cannabis currently has a consensus price target of $15.00, indicating a potential upside of 35.81%. Journey Medical has a consensus price target of $14.00, indicating a potential upside of 216.74%. Given Journey Medical’s stronger consensus rating and higher possible upside, analysts plainly believe Journey Medical is more favorable than Trulieve Cannabis.
Profitability
This table compares Trulieve Cannabis and Journey Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Trulieve Cannabis | -41.55% | -4.24% | -1.72% |
| Journey Medical | -8.95% | -20.23% | -6.60% |
Insider and Institutional Ownership
7.2% of Journey Medical shares are owned by institutional investors. 3.8% of Trulieve Cannabis shares are owned by company insiders. Comparatively, 14.5% of Journey Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Journey Medical beats Trulieve Cannabis on 8 of the 13 factors compared between the two stocks.
About Trulieve Cannabis
Trulieve Cannabis Corp. is a U.S. cannabis company that cultivates, processes and sells cannabis products through a vertically integrated business. Its offerings include flower, concentrates, vape products, edibles and other cannabis products, sold under brands such as Trulieve and Modern Flower. Founded in Florida in 2015, the company built its business in that state and expanded into other U.S. markets, including Arizona and Pennsylvania. Its operations and product offerings are shaped by the regulations in each state where it operates.
About Journey Medical
Journey Medical Corporation is a commercial-stage pharmaceutical company focused on developing and commercializing prescription products for medical dermatology. The company targets conditions that affect the skin, hair and nails, with an emphasis on products that address significant patient needs and can be marketed through its specialty sales organization. Its portfolio includes Qbrexza (glycopyrronium) cloth, a topical treatment for primary axillary hyperhidrosis, and Targadox (doxycycline hyclate) delayed-release capsules, which are used to treat moderate-to-severe inflammatory acne vulgaris.
Receive News & Ratings for Trulieve Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trulieve Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.
